# Lynozyfic (linvoseltamab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/linvoseltamab

> Lynozyfic (linvoseltamab), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), received a complete response letter from the FDA; the decision is dated Aug 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Lynozyfic (linvoseltamab) |
| Codes | REGN5458 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Relapsed and/or Refractory Multiple Myeloma (RRMM)](https://sec-api.dev/indications/relapsed-and-or-refractory-multiple-myeloma-rrmm) |
| Modality | antibody |
| FDA designations | accelerated |

## Timeline

### Aug 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2025-02-05, last confirmed 2025-04-29.
- SEC Form 10-Q (accession 0001804220-25-000022): "For example, in August 2024, the FDA issued a CRL concerning the Company's BLA for linvoseltamab in relapsed/refractory multiple myeloma due to findings from a pre-approval inspection at a third-party fill/finish provider for another company's product candidate." https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm
- SEC Form 10-Q (accession 0001804220-25-000022): "For example, in August 2024, the FDA issued a CRL concerning the Company's BLA for linvoseltamab in relapsed/refractory multiple myeloma due to findings from a pre-approval inspection" https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm
- SEC Form 10-K (accession 0001804220-25-000011): "For example, in August 2024, the FDA issued a CRL concerning the Company's BLA for linvoseltamab in relapsed/refractory multiple myeloma due to findings from a pre-approval inspection at a third-party fill/finish provider for another company's product candidate." https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231.htm

### Jan 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-02-04, last confirmed 2025-02-05.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000007): "•In January 2025, the Company resubmitted to the FDA the BLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in relapsed/refractory (R/R) multiple myeloma following resolution of third-party manufacturing issues." https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm
- SEC Form 10-K (accession 0001804220-25-000011): "In January 2025, the Company resubmitted the BLA following resolution of third-party manufacturing issues, and an FDA decision on the BLA is anticipated by mid-2025." https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231.htm

### July 10, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-02-04, last confirmed 2025-04-29.
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000020): "•The FDA accepted for review the resubmission of the BLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in R/R multiple myeloma, with a target action date of July 10, 2025." https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm
- Press release filed with the SEC (EX-99) (accession 0001804220-25-000007): "FDA decision on BLA for linvoseltamab (BCMA and CD3 bispecific antibody) in R/R multiple myeloma (mid-2025)" https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm
- SEC Form 10-K (accession 0001804220-25-000011): "In January 2025, the Company resubmitted the BLA following resolution of third-party manufacturing issues, and an FDA decision on the BLA is anticipated by mid-2025." https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231.htm
- SEC Form 10-Q (accession 0001804220-25-000022): "-FDA decision on BLA for relapsed/refractory multiple myeloma (target action date of July 10, 2025)" https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Relapsed and/or Refractory Multiple Myeloma (RRMM).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07222761 (A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07222761

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Relapsed and/or Refractory Multiple Myeloma (RRMM).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07222761 (A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07222761

Calendar months: [July 2025](https://sec-api.dev/fda-calendar/2025-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/linvoseltamab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lynozyfic (linvoseltamab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/linvoseltamab

```bibtex
@misc{secapidev_pdufa_linvoseltamab_20261116,
  title        = {Lynozyfic (linvoseltamab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/linvoseltamab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_linvoseltamab_20261116","title":"Lynozyfic (linvoseltamab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/linvoseltamab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
